LL-37

LL-37 Molecular Structure & Chemical Properties

LL-37 peptide represents the only human cathelicidin antimicrobial peptide identified to date, distinguished by its exceptional multifunctionality beyond direct pathogen elimination. Originally discovered in the 1990s through investigations of neutrophil granule contents, this 37-amino acid peptide has demonstrated remarkable stability and diverse biological activities spanning antimicrobial defense, wound healing, and immunomodulation. Unlike most antimicrobial peptides that function solely through membrane disruption, LL-37 exhibits both direct bactericidal properties and complex immunoregulatory effects that position it uniquely within the innate immune system. The peptide derives from proteolytic cleavage of the larger precursor protein hCAP-18 (human cationic antimicrobial protein 18 kDa) by proteinase 3, generating the active C-terminal fragment that has sustained intensive research interest across multiple disciplines including infectious disease, dermatology, and wound care.

Chemical Structure

2D molecular structure (Source: PubChem)

Technical Specifications

The peptide adopts an alpha-helical conformation in membrane environments, with a net positive charge of +6 at physiological pH that enables electrostatic interactions with negatively charged bacterial membranes. LL-37’s amphipathic structure – featuring distinct hydrophobic and hydrophilic faces – underlies its ability to insert into lipid bilayers and form various membrane-disrupting structures.

LL-37 Mechanism of Action

LL-37 peptide exerts its biological effects through multiple interconnected mechanisms that extend far beyond simple membrane disruption. Current research demonstrates that this peptide functions as a multifaceted immune mediator rather than a conventional single-target antimicrobial agent, with activities that span direct pathogen elimination, immune cell recruitment and activation, and tissue repair processes.

Primary Antimicrobial Mechanisms

Membrane Disruption – Direct Bactericidal Activity

Research has established that LL-37 employs diverse membrane-disrupting mechanisms depending on lipid composition and target cell type¹. The peptide’s primary antimicrobial action involves:

• Electrostatic binding to negatively charged bacterial membrane components including lipopolysaccharide (LPS) and lipoteichoic acid (LTA)
• Pore formation in membranes containing unsaturated lipids or cholesterol, causing rapid cell lysis
• Carpet mechanism on saturated lipid membranes, leading to membrane solubilization at threshold concentrations
• Intracellular targeting through membrane permeation to interact with nucleic acids and other cytoplasmic components²

Studies using electron microscopy and time-lapse imaging revealed that LL-37 perforates both outer and inner membranes of Gram-negative bacteria in a time-dependent manner, distinguishing its mechanism from other antimicrobial peptides³.

Immunomodulation – TLR Pathway Regulation

LL-37 demonstrates complex immunoregulatory properties through modulation of Toll-like receptor (TLR) signalingâ´:

• Inhibition of TLR2 and TLR4 activation by sequestering bacterial lipids (LTA and LPS), preventing excessive inflammatory responses
• Enhancement of TLR3, TLR7, TLR8, and TLR9 signaling by forming complexes with nucleic acids that protect them from degradation
• Dose-dependent effects on cytokine production, with low concentrations promoting homeostatic responses and higher concentrations inducing chemotaxis
• Context-dependent immune modulation where effects vary based on the activation state of target cells

Cell Migration and Chemotaxis

Investigations have shown LL-37 peptide functions as a potent chemoattractant for multiple immune cell typesâµ:

• Recruitment of neutrophils, monocytes, and T cells through formyl peptide receptor-like 1 (FPRL-1) activation
• Stimulation of keratinocyte migration via epidermal growth factor receptor (EGFR) transactivation
• Activation of focal adhesion kinase (FAK) and paxillin signaling pathways that regulate cell adhesion and movement
• Induction of actin cytoskeleton remodeling essential for cellular migration to injury sites

Wound Healing and Angiogenesis

Research has documented LL-37’s role in promoting tissue repair through multiple pathwaysâ¶:

• Angiogenesis stimulation through vascular endothelial growth factor (VEGF) pathway activation
• Proliferation enhancement of epithelial cells and fibroblasts at wound sites
• Matrix metalloproteinase activation facilitating tissue remodeling
• Re-epithelialization promotion in both acute and chronic wound models

Biofilm Disruption

Studies have revealed LL-37’s ability to interfere with bacterial biofilm formation and maturationâ·:

• Inhibition of biofilm formation by common wound pathogens including Staphylococcus aureus and Pseudomonas aeruginosa
• Disruption of established biofilms at concentrations below those required for direct bactericidal activity
• Modulation of bacterial twitching motility that affects biofilm architecture
• Potential synergistic effects with conventional antibiotics against biofilm-associated infections

LL-37 Research Applications & Key Findings

Antimicrobial and Anti-Biofilm Research

Bacterial Infection Studies

Extensive research in vitro and in animal models has examined LL-37’s antimicrobial spectrum and efficacyâ¸. Key findings include:

• Broad-spectrum activity against Gram-positive bacteria (Staphylococcus aureus, including MRSA), Gram-negative bacteria (Pseudomonas aeruginosa, Escherichia coli), and some fungal pathogens
• Synergistic effects with conventional antibiotics including beta-lactams and aminoglycosides in bacterial killing assays
• Enhanced lysozyme activity against Gram-positive pathogens through cooperative mechanisms
• Effective concentrations typically ranging from 1-10 micromolar in vitro, though tissue concentrations and activity in vivo remain incompletely characterized

Biofilm Research Applications

Investigations using polymicrobial biofilm models demonstrated LL-37’s potential against complex infectionsâ¹:

• Inhibition of biofilm formation by up to 68% when delivered via nanoparticle carriers compared to free peptide
• Downregulation of biofilm-associated genes including the ica operon responsible for polysaccharide intercellular adhesin synthesis
• Activity against preformed biofilms suggesting potential applications beyond prophylaxis
• Concentration-dependent effects with anti-biofilm activity at lower doses than required for direct bacterial killing

Wound Healing Research

Acute Wound Studies

Research in multiple animal models has evaluated LL-37’s wound healing properties¹â°:

• Accelerated wound closure in mouse excisional wound models, with topical application improving re-epithelialization rates
• Enhanced granulation tissue formation and collagen deposition at healing sites
• Increased vascularization through VEGF and hypoxia-inducible factor-1 alpha (HIF-1 alpha) upregulation
• Improved healing in immunocompromised models including diabetic mice

Chronic Wound Applications

Investigations into hard-to-heal wounds revealed variable efficacy patterns¹¹:

• Phase I/II human trials in venous leg ulcers showed dose-dependent effects, with 0.5 mg/mL and 1.6 mg/mL doses demonstrating improved healing parameters
• Larger phase IIb trial in 148 patients with venous leg ulcers did not show significant improvement in the full study population
• Post hoc analysis suggested potential benefit in subgroups with large wounds (greater than 10 square cm), a known negative prognostic factor
• Safety profile was favorable with no significant local or systemic adverse events reported

Infectious Disease Research

Respiratory Infection Studies

Research in pulmonary infection models demonstrated LL-37’s role in airway defense¹²:

• Expression in airway epithelium with levels modulated by vitamin D status and inflammatory conditions
• Protection against respiratory pathogens including Pseudomonas aeruginosa in pneumonia models
• Neutralization of bacterial endotoxins reducing LPS-induced inflammatory damage
• Wound healing promotion in damaged airway epithelium through EGFR-mediated pathways

Gastrointestinal Infection Research

Investigations in enteric disease models revealed protective effects in the digestive tract¹³:

• Downregulation during Shigella infections representing a potential immune escape mechanism
• Improved outcomes when endogenous LL-37 expression was induced by butyrate treatment in animal models
• Protection against pathogen colonization in intestinal epithelium
• Modulation of gut microbiota composition, though mechanisms remain under investigation

Urinary Tract Defense Studies

Research documented LL-37’s protective role against urinary infections¹â´:

• Constitutive expression in urinary tract epithelium providing continuous defense
• Protection against uropathogens including E. coli in bladder infection models
• Deficiency association with increased susceptibility to recurrent urinary tract infections
• Vitamin D-dependent regulation of expression levels in urinary epithelial cells

Cancer and Autoimmune Research

Cancer Cell Studies

Investigations have examined LL-37’s complex and sometimes contradictory roles in cancer biology¹âµ:

• Cytotoxic effects on colon cancer cells through caspase-independent apoptosis induction
• Tumor suppression in some models through bone morphogenetic protein signaling modulation
• Pro-tumorigenic effects in other contexts, particularly ovarian cancer, through FPRL-1 receptor activation
• Context-dependent outcomes suggesting tissue-specific and concentration-dependent mechanisms

Autoimmune Disease Research

Studies in autoimmune models revealed LL-37’s involvement in inflammatory disorders¹â¶:

• Elevated levels in psoriatic lesions, potentially contributing to inflammation through nucleic acid complex formation
• Association with lupus and rheumatoid arthritis, though causative versus correlative relationship remains unclear
• Protective effects in some arthritis models when administered exogenously
• Complex role in balancing pro-inflammatory and anti-inflammatory responses

LL-37 Pharmacokinetics & Metabolism

Absorption & Distribution

LL-37 exhibits pharmacokinetic properties that remain incompletely characterized, particularly in human systems¹â·. Available research from animal models and in vitro studies indicates:

• Topical application results in local tissue retention with variable systemic absorption depending on formulation and application site
• Mucosal delivery including oral and inhalation routes shows promise in preclinical models, though bioavailability data remain limited
• Tissue distribution patterns suggest preferential accumulation at sites of inflammation or infection
• Encapsulation strategies using nanoparticles or hydrogels significantly enhance stability and prolong local activity compared to free peptide

Studies using radiolabeled peptide in animal models demonstrated concentration at wound sites and in inflammatory tissues, suggesting some degree of targeted delivery¹â¸.

Metabolism & Elimination

The metabolic fate of LL-37 presents significant challenges for therapeutic development¹â¹:

• Rapid proteolytic degradation by various proteases in biological fluids limits peptide half-life to minutes in unprotected formulations
• Enzyme-specific cleavage by kallikreins, elastase, and other serine proteases generates fragments with altered activity profiles
• Clearance mechanisms likely involve both proteolytic breakdown and renal filtration, though detailed kinetic studies in humans are absent
• Modified analogs including D-amino acid variants and cyclized structures demonstrate enhanced protease resistance

The disconnect between short half-life and prolonged biological effects observed in some models suggests either sustained signaling cascade activation, formation of active metabolites, or tissue sequestration mechanisms that require further investigation.

Excretion Pathways

Limited data on LL-37 excretion indicates:

• Renal elimination of intact peptide and fragments likely contributes to clearance
• Metabolic breakdown products generated by proteolytic cleavage represent the primary elimination pathway
• Clearance rates vary substantially based on tissue environment and proteolytic activity
• Accumulation has not been reported in chronic dosing studies in animal models, though long-term human data are absent

LL-37 Research Protocols & Administration

Dosing in Published Research

Research investigations have employed diverse LL-37 concentrations across different experimental systems:

• In vitro antimicrobial assays: 1-10 micromolar typical effective concentration range; minimum inhibitory concentrations vary by pathogen
• Cell culture wound healing studies: 1-5 micrograms per mL for optimal proliferation and migration effects
• Mouse models: Topical application of 10-50 micrograms per wound or systemic delivery at various doses depending on model
• Human wound healing trials: 0.5, 1.6, and 3.2 mg/mL applied topically twice weekly, with lower doses showing better efficacy profiles

Important: These are experimental concentrations and dosing regimens used in research settings and cannot be extrapolated to other species or clinical applications due to significant differences in peptide metabolism, protease activity, immune system organization, tissue distribution, and pharmacokinetic parameters. Species-specific factors profoundly influence both efficacy and safety profiles, and optimal human dosing remains undefined.

Administration Routes in Research

Multiple delivery methods have been investigated in preclinical and clinical studies:

• Topical application – Most common route for wound healing research; used in human trials for chronic leg ulcers
• Subcutaneous injection – Employed in some animal infection models for systemic delivery
• Inhalation – Investigated for respiratory infection prevention and treatment in animal models
• Oral delivery – Examined for gastrointestinal applications, though bioavailability challenges limit efficacy
• Encapsulated formulations – Nanoparticle, hydrogel, and polymer-based carriers enhance stability and prolong activity
• Gene therapy approaches – Adenoviral delivery of LL-37 or precursor hCAP-18 explored in experimental wound models

Common Model Organisms

LL-37 and related cathelicidin peptides have been studied across multiple experimental systems:

• Cell culture – Human keratinocytes (HaCaT), colonic epithelial cells (HT-29), endothelial cells, macrophages, neutrophils
• Mice – C57BL/6, BALB/c, and diabetic (ob/ob) strains for wound healing, infection, and autoimmune models
• Rabbits – Shigella infection models, pressure ulcer studies, gastrointestinal research
• Rats – Limited studies compared to other species
• Human subjects – Small clinical trials for venous leg ulcers; various observational studies examining endogenous LL-37 levels in disease states
• Bacterial and fungal cultures – In vitro antimicrobial and biofilm assays across diverse pathogen species

Research Limitations & Regulatory Status

Critical Gaps in Current Evidence

Despite substantial preclinical investigation spanning over two decades, LL-37 faces significant translational barriers that limit its immediate therapeutic utility.

Lack of Human Clinical Data

The most substantial limitation is the paucity of completed human clinical trials:

• Only two published phase I/II trials examining topical application for venous leg ulcers, with mixed efficacy results
• No phase III trials completed or published in peer-reviewed literature
• Human pharmacokinetics remain largely uncharacterized beyond topical wound applications
• Optimal dosing regimens for human therapeutic use undefined across indications
• Long-term safety data in human subjects absent beyond short-term wound healing trials

Mechanistic Understanding Gaps

Fundamental aspects of LL-37’s mechanism remain incompletely understood:

• Receptor specificity across various cell types and biological activities not fully elucidated
• Structure-activity relationships for different biological functions require further investigation
• Dose-response relationships in vivo complicated by simultaneous antimicrobial, immunomodulatory, and wound healing effects
• Interaction with the microbiome and potential impacts on commensal bacterial populations inadequately studied
• Active metabolite identification and their contributions to biological effects unclear

Therapeutic Development Challenges

Several obstacles hinder therapeutic translation:

• Rapid proteolytic degradation in biological fluids necessitates protective formulations or chemical modifications
• Cost of production for peptides remains substantially higher than small molecule drugs
• Dose optimization complicated by multiple biological activities occurring across different concentration ranges
• Context-dependent effects including pro-tumorigenic activities in some cancer models raise safety concerns
• Autoimmune associations in psoriasis and other inflammatory conditions require careful evaluation

Long-Term Safety Considerations

Critical safety questions remain unanswered:

• Effects of chronic administration beyond several weeks unstudied even in animal models
• Impact on commensal microbiota and potential development of dysbiosis with prolonged use
• Immunogenicity potential with repeated dosing unclear, particularly for modified analogs
• Cancer risk assessment required given contradictory effects in different tumor models
• Resistance development by pathogens, though theoretically less likely than with conventional antibiotics, remains to be evaluated in long-term studies

Regulatory & Competitive Sport Status

FDA Position

LL-37 has not received FDA approval for any therapeutic indication:

• Not approved for human therapeutic use or medical applications
• Classification as an investigational new drug for ongoing clinical research
• Not approved for compounding in the United States
• Research use only designation for commercially available peptide

WADA Prohibition

World Anti-Doping Agency classification status:

• Not specifically listed as a prohibited substance in current WADA regulations as of 2025
• Antimicrobial peptides generally not regulated under anti-doping codes
• Potential future consideration depending on evidence of performance-enhancing effects
• Athletes should verify current status with appropriate regulatory authorities before use

Research Classification: LL-37 is available only for laboratory research use. It is not intended for human consumption, medical use, or veterinary applications. All research must be conducted under appropriate ethical oversight and regulatory compliance with institutional review board approval where applicable.

>Lead Researcher Spotlight

Professor Birgitta Agerberth, PhD

Professor of Medical Microbial Pathogenesis

Karolinska Institutet, Stockholm, Sweden

Professor Birgitta Agerberth has been a pioneering figure in cathelicidin research since the 1990s, leading investigations that have fundamentally shaped our understanding of LL-37’s role in human innate immunity. Her laboratory at Karolinska Institutet has published seminal work characterizing this peptide’s antimicrobial properties, immunomodulatory functions, and involvement in human health and disease. Appointed Professor of Medical Microbial Pathogenesis in 2008, Professor Agerberth’s research program has focused on understanding how the innate immune system maintains host-microbe homeostasis despite constant exposure to potential pathogens.

Professor Agerberth’s major research contributions include:

• Discovery and characterization of LL-37 as the sole human cathelicidin, establishing its antimicrobial spectrum and structural properties
• Elucidation of regulatory mechanisms controlling LL-37 expression, including vitamin D-dependent pathways and transcriptional regulation
• Investigation of immunomodulatory functions beyond direct antimicrobial activity, revealing LL-37’s role in inflammation regulation
• Clinical translation efforts examining LL-37 induction as a therapeutic strategy for infectious diseases
• Collaborative research spanning infectious diseases, dermatology, gastroenterology, and immunology

Her work has established LL-37 as one of the most comprehensively studied antimicrobial peptides in humans, though she has consistently emphasized the need for rigorous clinical validation before therapeutic applications can be realized.

Disclaimer: This spotlight is provided for educational purposes to acknowledge scientific contributions to LL-37 research. Cenexa Labs has no affiliation with Professor Agerberth or Karolinska Institutet, and this information does not constitute an endorsement of any products or services.

References

1. Shahmiri, M., Enciso, M., Adda, C.G., Smith, B.J., Perugini, M.A., & Mechler, A. (2016). Membrane core-specific antimicrobial action of cathelicidin LL-37 peptide switches between pore and nanofibre formation. Scientific Reports, 6, 38184. PubMed
   
2. Xhindoli, D., Pacor, S., Benincasa, M., Scocchi, M., Gennaro, R., & Tossi, A. (2016). The human antimicrobial peptide LL-37 – A pore-forming antibacterial agent and host-cell modulator. Biochimica et Biophysica Acta, 1858(3), 546-566. PubMed
   
3. Morgera, F., Antcheva, N., Pacor, S., Quaroni, L., Berti, F., Vaccari, L., & Tossi, A. (2020). The structure of the antimicrobial human cathelicidin LL-37 shows oligomerization and channel formation in the presence of membrane mimics. Scientific Reports, 10, 17356. PubMed
   
4. Scheenstra, M.R., van Harten, R.M., Veldhuizen, E.J.A., Haagsman, H.P., & Coorens, M. (2020). Cathelicidins modulate TLR-activation and inflammation. Frontiers in Immunology, 11, 1137. PubMed
   
5. Yang, D., Chertov, O., Bykovskaia, S.N., Chen, Q., Buffo, M.J., Shogan, J., Anderson, M., Schroder, J.M., Wang, J.M., Howard, O.M., & Oppenheim, J.J. (2000). LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. Journal of Experimental Medicine, 192(7), 1069-1074. PubMed
   
6. Carretero, M., Escámez, M.J., García, M., Duarte, B., Holguín, A., Retamosa, L., Jorcano, J.L., del Río, M., & Larcher, F. (2008). In vitro and in vivo wound healing-promoting activities of human cathelicidin LL-37. Journal of Investigative Dermatology, 128(1), 223-236. PubMed
   
7. Dean, S.N., Bishop, B.M., & van Hoek, M.L. (2011). Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against Staphylococcus aureus. BMC Microbiology, 11, 114. PubMed
   
8. Dürr, U.H., Sudheendra, U.S., & Ramamoorthy, A. (2006). LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochimica et Biophysica Acta, 1758(9), 1408-1425. PubMed
   
9. Khaleghian, A., Ahmadi, F., Jahromi, B.M., & Salami, M. (2022). Delivery LL37 by chitosan nanoparticles for enhanced antibacterial and antibiofilm efficacy. Carbohydrate Polymers, 291, 119626. PubMed
   
10. Steinstraesser, L., Koehler, T., Jacobsen, F., Daigeler, A., Goertz, O., Langer, S., Kesting, M., Steinau, H., Eriksson, E., & Hirsch, T. (2008). Host defense peptides in wound healing. Molecular Medicine, 14(7-8), 528-537. PubMed
    
11. Grönberg, A., Mahlapuu, M., Ståhle, M., Whately-Smith, C., & Rollman, O. (2014). Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial. Wound Repair and Regeneration, 22(5), 613-621. PubMed
    
12. Tjabringa, G.S., Ninaber, D.K., Drijfhout, J.W., Rabe, K.F., & Hiemstra, P.S. (2006). Human cathelicidin LL-37 is a chemoattractant for eosinophils and neutrophils that acts via formyl-peptide receptors. International Archives of Allergy and Immunology, 140(2), 103-112. PubMed
    
13. Raqib, R., Sarker, P., Bergman, P., Ara, G., Lindh, M., Sack, D.A., Nasirul Islam, K.M., Gudmundsson, G.H., Andersson, J., & Agerberth, B. (2006). Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. Proceedings of the National Academy of Sciences, 103(24), 9178-9183. PubMed
    
14. Chromek, M., Slamová, Z., Bergman, P., Kovács, L., Podracká, L., Ehrén, I., Hökfelt, T., Gudmundsson, G.H., Gallo, R.L., Agerberth, B., & Brauner, A. (2006). The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nature Medicine, 12(6), 636-641. PubMed
    
15. Coffelt, S.B., Tomchuck, S.L., Zwezdaryk, K.J., Danka, E.S., & Scandurro, A.B. (2009). Leucine leucine-37 uses formyl peptide receptor-like 1 to activate signal transduction pathways, stimulate oncogenic gene expression, and enhance the invasiveness of ovarian cancer cells. Molecular Cancer Research, 7(6), 907-915. PubMed
    
16. Lande, R., Gregorio, J., Facchinetti, V., Chatterjee, B., Wang, Y.H., Homey, B., Cao, W., Wang, Y.H., Su, B., Nestle, F.O., Zal, T., Mellman, I., Schröder, J.M., Liu, Y.J., & Gilliet, M. (2007). Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature, 449(7162), 564-569. PubMed
    
17. Bucki, R., Leszczynska, K., Namiot, A., & Sokolowski, W. (2010). Cathelicidin LL-37: a multitask antimicrobial peptide. Archivum Immunologiae et Therapiae Experimentalis, 58(1), 15-25. PubMed
    
18. Li, X., Li, Y., Han, H., Miller, D.W., & Wang, G. (2006). Solution structures of human LL-37 fragments and NMR-based identification of a minimal membrane-targeting antimicrobial and anticancer region. Journal of the American Chemical Society, 128(17), 5776-5785. PubMed
    
19. van der Does, A.M., Bergman, P., Agerberth, B., & Lindbom, L. (2012). Induction of the human cathelicidin LL-37 as a novel treatment against bacterial infections. Journal of Leukocyte Biology, 92(4), 735-742. PubMed
    

All references open in new window. These citations are provided for educational and research purposes only. This information is not intended to diagnose, treat, cure, or prevent any disease. LL-37 is intended for laboratory research use only.